- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01895816
Herbal Tonic Fertile Supplement(ZO2C5) ((ZO2C5))
July 11, 2013 updated by: Arash Khaki
Phase 3 of Study on Effects of New Herbal Mixture on Men Infertility
The purpose of this study is to determine whether the effect of mixed herbals drug (citrus, citrolus vol, lan, carrot seed, zingiber, onion, basil, cinnamon) administration on male infertility: oligospermia
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In the last few years, a marked decrease in the quality of semen has been reported.
Infertility is one of the major health problems in 10 to 15% of couples' lives; from which approximately 50% of couple's infertility is due to Male factors.
The aim of the present study was to evaluate an herbal mixed effects on spermatogenesis and the normal production of sperm.
Researchers have reported that using antioxidants and vitamins A, B, C, E, flavonoids, Sulfur compounds, terpenoids and phenolic compounds in the daily diet can protect sperm.
In this study the investigators aimed to assess synergistic effect of these herbal compounds in male Infertility.
700 mg tablet for 180 consequence days/daily will be advising, for 40 patients semen samples in 1th and 180 day after treatment will take, in andrology lab according WHO method:samples put into 2 mL of medium (Hams F10) containing 0.5% bovine serum albumin.
After 5 min incubation at 37oC (with 5% CO), the sperm samples were determined using the standard haemocytometric method, and sperm motility was analyzed by microscope (Olympus IX70) at 10 field and reported as the mean of motile sperm according to WHO methods .
The sperm abnormality was evaluated according to the standard method of Narayana .Briefly, smears of the sperm suspension were made on clean glass slides and stained with periodic acid-Schiff's reaction haematoxylin.
The stained smears were observed under a light microscopic with 40× magnification.
The sperms were classified into normal and abnormal.
The total sperm abnormality was expressed as percentage incidence.
Other biochemical tests will be doing according the our research protocol and thesis for blood samples for measure LH, Testosterone, TAC, Glc and Cholesterol.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Azarbyjan
-
Tabriz, Azarbyjan, Iran, Islamic Republic of, 51388
- Womens Reproductive Health Research Center,Tabriz University Of Medical Sciences,Iran
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- all patients suffering from oligospermia are included
Exclusion Criteria:
- any diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: fertility coated tablet
700 mg fertility coated tablet containing 8 herbal powders by mouth every 12 hours for 180 days
|
this supplement contains 700 mg of 8 natural herbals: Citrus & ZINGIBER OFFICINALE & Onion & Ocimum basilicum & Cinnamomum zelanicum & Citrullus lanatus & Citrullus vulgaris & Daucus carota
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sperm count variation
Time Frame: First day of research, 2th time for sampling is 180 days after treatment
|
Semen analysis according WHO methods
|
First day of research, 2th time for sampling is 180 days after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sperm motility
Time Frame: 1th time in first day of research, 2th time after 180 days of treatment
|
Semen analysis
|
1th time in first day of research, 2th time after 180 days of treatment
|
|
Sperm Viability
Time Frame: 1th time in first day of research, 2th time after 180 days of treatment
|
Semen analysis
|
1th time in first day of research, 2th time after 180 days of treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Testosterone levels
Time Frame: 1th time in first day of research, 2th time after 180 days of treatment
|
Testosterone analysis
|
1th time in first day of research, 2th time after 180 days of treatment
|
|
Serum Total antioxidant levels
Time Frame: 1th time in first day of research, 2th time after 180 days of treatment
|
Total antioxidant measurement in serum
|
1th time in first day of research, 2th time after 180 days of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Arash Khaki, PhD, Women Reproductive Health Research Center,Tabriz University of medical Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
September 12, 2012
First Submitted That Met QC Criteria
July 7, 2013
First Posted (Estimate)
July 11, 2013
Study Record Updates
Last Update Posted (Estimate)
July 12, 2013
Last Update Submitted That Met QC Criteria
July 11, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- WRHRC-9026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Infertility
-
Szeged UniversityEnrolling by invitation
-
Medipol UniversityNot yet recruitingMale Infertility | Unexplained Infertility | Sperm DNA Fragmentation
-
South Valley UniversityActive, not recruitingMale Infertility | OligoasthenozoospermiaEgypt
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Fecundis Lab SLRecruitingMale Infertility | Reproductive Issues | ICSI | Infertility (IVF Patients) | IVF OutcomesSpain
-
University of Medicine and Pharmacy at Ho Chi Minh...RecruitingMale Infertility With OATVietnam
-
Reproductive Medicine Associates of New JerseyTerminated
-
Jinling Hospital, ChinaRecruitingMale Infertility Due to HypospermatogenesisChina
-
Sapientiae InstituteTerminated
Clinical Trials on coated tablet
-
Galapagos NVTerminatedSystemic Lupus ErythematosusSpain, Bulgaria, Moldova, Republic of, Poland, Ukraine
-
Heronova PharmaceuticalsCompletedCOVID-19 | Coronavirus InfectionChina
-
LG ChemCompleted
-
Humanis Saglık Anonim SirketiCompleted
-
AstraZenecaQuotient SciencesCompletedHealthy VolunteersUnited Kingdom
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruitingHepatic Insufficiency | Renal Insufficiency | ElderlyChina
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruiting
-
PfizerRecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionBelgium
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed
-
Pharmaceutical Research Unit, JordanAbdi Ibrahim Ilac San. ve Tic A.S.Completed